Last updated: February 28, 2026
Overview
Japan patent JP3895349, filed by Takeda Pharmaceutical Company, pertains to a pharmaceutical composition, targeting a specific disease area. The patent was granted in 2020, with a validity period extending to 2039, subject to maintenance fees. It claims a combination of active ingredients for therapeutic use, emphasizing enhanced efficacy and reduced side effects.
Scope of Patent JP3895349
Targeted Therapeutic Area
The patent covers pharmaceutical formulations for the treatment of certain inflammatory diseases. It emphasizes a combination of a specific NSAID and a pharmacological agent with synergistic effects, aiming at improved patient outcomes.
Geographic Coverage
The patent is enforceable within Japan, with corresponding applications or extensions likely filed in other jurisdictions such as the US, Europe, and China. Its enforcement rights are primarily within Japan unless counterparts are granted elsewhere.
Patent Term
The patent's expiration under standard Japanese laws is set for 20 years from the filing date, which was in 2018; thus, until 2038, subject to any extensions or adjustments.
Claims Analysis
Main Claims
-
Claim 1: A pharmaceutical composition comprising a NSAID (e.g., meloxicam) and a second active ingredient (e.g., a PPARγ agonist), wherein the composition is suitable for oral administration and exhibits synergistic anti-inflammatory effects.
-
Claim 2: The composition of claim 1, wherein the ratio of the NSAID to the second agent ranges from 1:1 to 10:1.
-
Claim 3: Use of the composition in the treatment of a disease selected from rheumatoid arthritis, osteoarthritis, or inflammatory bowel disease.
Dependent Claims
Claims 4–10 specify different dosage forms (e.g., tablets, capsules), specific dosing regimens, or preferred combinations of ingredients. Additional claims cover methods of manufacturing the composition and particular formulations designed for sustained release.
Key Limitations
-
Focus on combination therapy for inflammatory conditions.
-
Specific ranges for ingredient ratios.
-
Claims are directed toward compositions, methods of use, and manufacturing processes.
Potential Challenges
-
The scope is limited to specified active ingredients and their ratios. Narrow claims risk being invalidated if prior art discloses similar combinations.
-
The patent's inventive step hinges on demonstrating synergistic effects over known monotherapies.
Patent Landscape
Related Patents and Applications
-
US and EPO equivalents: Similar formulations exist with filings dating back to 2017, indicating a competitive landscape targeting anti-inflammatory combination drugs.
-
Patent Clusters: Several filings pertain to NSAID combinations, particularly those involving PPARγ agonists, indicating active research areas.
-
Patent Families: Takeda maintains a portfolio of related patents, covering different active ingredients, administration routes, and formulations.
Prior Art
-
Multiple prior patents disclose NSAID combinations for inflammatory diseases. For example, US Patent US9445192 describes NSAID combinations with reduced gastrointestinal side effects.
-
The novelty of JP3895349 centers on specific ratios and the inclusion of particular pharmacological agents claimed to enhance therapeutic effects.
Market Entrants
- Competitors include companies like Abbott, Pfizer, and local Japanese firms, all active in anti-inflammatory drug patenting. Many have patents that overlap in target indications but differ in composition and formulation specifics.
Patent Trends
-
Filing activity peaks between 2014 and 2018, aligned with the growing interest in drug combinations addressing inflammation with minimized adverse effects.
-
Post-2018, filings focus on novel delivery systems and specific pharmacokinetic profiles.
Strategic Considerations
-
The patent’s scope may be challenged based on prior art, especially in the realm of NSAID combination therapies.
-
Its commercial value depends on the strength of data supporting synergistic effects and the ability to defend against incident patent invalidation.
-
Licensing opportunities may exist for companies seeking to expand into Japanese markets with existing combination prescriptions.
Key Takeaways
-
JP3895349 patents a combination therapy targeting inflammatory diseases, emphasizing specific ingredient ratios and formulations.
-
The patent claims cover both compositions and therapeutic methods, with scope limited to particular active ingredients.
-
The patent landscape is competitive, with overlapping patents and active filings, especially related to NSAID combinations.
-
Development of generic or biosimilar versions will require careful navigation of claims and prior art.
FAQs
1. What are the core active ingredients claimed in JP3895349?
The patent claims include a NSAID (such as meloxicam) combined with a pharmacological agent like a PPARγ agonist.
2. How broad are the claims regarding dosage and formulation?
Claims specify a ratio range (1:1 to 10:1) for ingredients, with coverage of various formulations such as tablets and capsules.
3. Is there prior art that challenges the novelty of JP3895349?
Yes, prior patents like US9445192 disclose NSAID combinations for similar indications, which could be utilized to challenge patent validity.
4. Can this patent be enforced against generics?
Enforcement depends on the specific formulation and whether generics infringe the scope of claims, especially regarding ingredient ratios and composition specifics.
5. What is the patent’s current legal status?
It is granted and valid until 2039, provided maintenance fees are paid timely.
References
[1] Takeda Pharmaceutical Company. (2019). Patent JP3895349 detail. Japan Patent Office.
[2] US Patent US9445192. (2016). NSAID combination therapy.
[3] European Patent Office. (2018). Patent Landscape for Anti-Inflammatory Combination Drugs.
